Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312895 | 1.00 | KCNH2 (0.50) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL7031873 | 1.00 | KCNH2 (0.50) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11084696 | 0.98 | KCNH2 (0.49) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL4074900 | 0.91 | KCNH2 (0.49) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL9951699 | 0.86 | CHRNA7 (0.53) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL14615319 | 0.85 | KCNH2 (0.52) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL4075128 | 0.85 | KCNH2 (0.52) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL6002385 | 0.85 | KCNH2 (0.52) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL6003339 | 0.85 | KCNH2 (0.52) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL4073749 | 0.84 | KCNH2 (0.51) | KCNH2DRD2DRD3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745458-B2 | Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HTR5A, CHRNA5, DRD3 | KCNH2 464/4885DRD2 11/4885DRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.